DW71177

CAS No. 2241311-72-6

DW71177( —— )

Catalog No. M37566 CAS No. 2241311-72-6

DW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 296 Get Quote
5MG 459 Get Quote
10MG 657 Get Quote
25MG 994 Get Quote
50MG 1371 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    DW71177
  • Note
    Research use only, not for human use.
  • Brief Description
    DW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.
  • Description
    DW71177 is a novel [1,2,4]triazolo[4,3-a] quinoxaline-based potent and BD1-Selective BET inhibitor, and can be used for study of acute myeloid leukemia.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2241311-72-6
  • Formula Weight
    384.48
  • Molecular Formula
    C20H28N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NCCCCNC1=NC=2C=C(OC)C=CC2N3C1=NN=C3C)CC(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ali I, et al. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. Eur J Med Chem. Published online December 16, 2023.?
molnova catalog
related products
  • BRD7-IN-1

    BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), forms PROTAC VZ185 via linkage to a VHL ligand, demonstrating potent activity against BRD7/9 with DC50 values of 4.5 and 1.8 nM, respectively .

  • ZEN-3219

    ZEN-3219 is a BET inhibitor, which has inhibitory effect on BRD4(BD1), BRD4(BD2) and BRD4(BD1BD2).

  • BY27

    BY27, a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1/BD2 of BRD2, BRD3, BRD4, and BRDT, and suppresses tumor growth.